SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

Novartis (NVS)

NVS RSS Feed
Add NVS Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 7/23/2017 2:28:42 AM - Followers: 15 - Board type: Free - Posts Today: 0
NVS
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVS News: DURECT's Collaboration with Sandoz Clears HSR Review and is Effective 06/19/2017 07:00:00 AM
NVS News: Pharmaceutical Leaders Pave the Way to New Alzheimer’s Treatments 06/15/2017 07:00:00 AM
NVS News: DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) ... 05/08/2017 07:00:00 AM
PostSubject
#317  Sticky Note NVS 2Q17 CC slides: DewDiligence 07/18/17 01:36:07 PM
#320   https://seekingalpha.com/article/4089618-amgen-novartis-first-mover-advantage-mu Inoviorulez 07/23/17 02:28:42 AM
#319   Sell short this crap along with other big pharma... malt66 07/18/17 08:27:34 PM
#317   NVS 2Q17 CC slides: DewDiligence 07/18/17 01:36:07 PM
#316   https://seekingalpha.com/article/4087475-novartis-wins-fda-panel-backing-new-car Inoviorulez 07/13/17 10:07:15 AM
#315   NVS’ own PR on CTL019 ODAC panel: DewDiligence 07/13/17 09:44:32 AM
#314   FDA approves Tafinlar+Mekinist for BRAF-V600E NSCLC: #msg-132422635. DewDiligence 06/22/17 06:41:33 PM
#313   Ilaris reduces MACE in secondary-prevention setting: #msg-132398529. DewDiligence 06/22/17 09:12:42 AM
#312   RTH258 non-inferior to Eylea with less-frequent injections: #msg-132328161. DewDiligence 06/20/17 09:15:40 AM
#311   EU approves NVS’ Rituxan FoB, called Rixathon: DewDiligence 06/19/17 11:43:31 AM
#310   NVS “Meet the Management” Investor Day slides: DewDiligence 05/31/17 08:41:54 AM
#309   CHMP approves Zykadia in first-line ALK+ NSCLC: DewDiligence 05/19/17 10:08:45 AM
#308   https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555778.htm?source= mikekrane 04/28/17 12:17:29 PM
#307   NVS 1Q17 CC slides: DewDiligence 04/25/17 07:09:11 PM
#306   NVS could take $15-25B loss on Alcon sale: DewDiligence 04/21/17 11:23:13 AM
#305   NVS, AGN collaborate on phase-2b for NASH combo: #msg-130568056. DewDiligence 04/18/17 11:00:25 AM
#304   NVS licenses dry-eye drug candidate from (private) Lubris, DewDiligence 04/07/17 11:24:09 AM
#303   Serelaxin fails revamped phase-3 trial in acute HF: #msg-129752197. DewDiligence 03/22/17 09:44:43 AM
#302   FDA approves NVS’ Kisqali (f/k/a LEE011) for first-line DewDiligence 03/13/17 05:57:43 PM
#301   Novartis AG (ADR) (NYSE:NVS) Fined And Some Products trendmkr 03/03/17 12:56:01 PM
#300   Novartis AG (NYSE:NVS) Greater Use Of Technology In trendmkr 02/14/17 12:13:58 PM
#298   Some info about NVS’ RTH258 for AMD: #msg-128240149. DewDiligence 01/29/17 06:53:41 PM
#297   NVS CC slides… DewDiligence 01/25/17 07:04:17 AM
#296   NVS inks two deals… DewDiligence 12/20/16 09:43:21 AM
#295   Down nearly 4% in one day on good Ecomike 10/25/16 07:40:53 PM
#294   NVS 3Q16 CC slides: DewDiligence 10/25/16 10:25:03 AM
#293   NVS’ LEE011 data impress in first-line HR+/HER2- breast DewDiligence 10/08/16 04:45:07 PM
#292   NVS presents phase-3 data in SPMS: DewDiligence 09/18/16 03:56:47 PM
#291   NVS reduces MNTA stake via 10b5-1 plan: #msg-124870976. DewDiligence 08/30/16 05:57:38 PM
#290   What will NVS do about AMGN's Enbrel patent DewDiligence 08/30/16 05:56:51 PM
#289   FDA approves NVS’ Enbrel FoB, but... #msg-124870707. DewDiligence 08/30/16 05:35:31 PM
#288   NVS hits phase-3 primary endpoint in SPMS: DewDiligence 08/25/16 10:21:36 AM
#287   Novartis AG Licenses LGT209 To Cyon Therapeutics, Teams venturecapp 08/24/16 12:22:56 PM
#286   NVS’ recent-launch successes—Cosentyx yes, Entresto no: DewDiligence 07/19/16 11:24:57 AM
#285   FDA rejects NVS' Enbrel FoB: #msg-123963130. DewDiligence 07/19/16 10:31:47 AM
#284   NVS 2Q16 CC slides: DewDiligence 07/19/16 10:30:23 AM
#283   will be 90 by next year Fibanotch 06/10/16 05:11:59 PM
#282   Novartis, Eisai To Cooperate In Cancer Drugs Marketing venturecapp 06/08/16 10:50:38 AM
#281   NVS to run 40+ Entresto trials to boost sales: DewDiligence 05/19/16 04:10:33 PM
#280   $NVS recent news/filings stocktrademan 03/18/16 04:33:30 PM
#279   Entresto is off to a slow start: #msg-121250538. DewDiligence 03/16/16 06:20:43 PM
#278   Looks like Offices are being Raided over Bribery PENNYMACHINE 02/22/16 12:22:29 PM
#277   The 20-F annual report has been filed: DewDiligence 01/27/16 08:34:50 AM
#276   NVS 4Q15 CC slides: DewDiligence 01/27/16 07:08:54 AM
#275   Alcon has become a serious drag on NVS: #msg-119762239. DewDiligence 01/11/16 07:42:12 PM
#274   Entresto might increase risk of AMD and AD, DewDiligence 12/10/15 03:25:56 PM
#273   Novartis Reaffirms its CAR T Dominance venturecapp 12/07/15 12:29:48 PM
#272   FDA approves generic Gleevec from Sun Pharma: #msg-118939751. DewDiligence 12/04/15 12:50:56 PM
#271   FDA reviewing NVS’ 351(k) submission for Neulasta FoB: #msg-118583523. DewDiligence 11/18/15 10:18:57 AM
#270   AVEO 8-K filing today: Novartis AV-380 Inventory Reimbursement ProfitScout 11/16/15 07:33:49 PM
#269   NVS 10 MINUTES TREND1 11/12/15 09:44:37 PM
PostSubject